Immatics (NASDAQ:IMTX) vs. Anixa Biosciences (NASDAQ:ANIX) Head-To-Head Analysis

Immatics (NASDAQ:IMTX) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Insider & Institutional Ownership

64.4% of Immatics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 3.3% of Immatics shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Immatics and Anixa Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60 million	18.88	-$222.26 million	($1.86)	-4.05
Anixa Biosciences	$210,000.00	460.16	-$10.93 million	($0.32)	-8.69

Anixa Biosciences has lower revenue, but higher earnings than Immatics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Immatics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Profitability

This table compares Immatics and Anixa Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immatics	-495.71%	-47.41%	-39.45%
Anixa Biosciences	N/A	-76.59%	-67.80%

Analyst Recommendations

This is a breakdown of current recommendations for Immatics and Anixa Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1	0	7	0	2.75
Anixa Biosciences	1	1	3	0	2.40

Immatics currently has a consensus target price of $19.67, indicating a potential upside of 160.83%. Anixa Biosciences has a consensus target price of $8.00, indicating a potential upside of 187.77%. Given Anixa Biosciences’ higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Immatics.

Summary

Immatics beats Anixa Biosciences on 8 of the 14 factors compared between the two stocks.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

About Anixa Biosciences

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.